Amgen Inc (AMGN)
270.90
+2.03
(+0.76%)
USD |
NASDAQ |
Mar 18, 16:00
271.87
+0.97
(+0.36%)
Pre-Market: 08:27
Amgen Enterprise Value: 198.85B for March 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
March 18, 2024 | 198.85B |
March 15, 2024 | 197.76B |
March 14, 2024 | 199.19B |
March 13, 2024 | 201.58B |
March 12, 2024 | 201.87B |
March 11, 2024 | 201.24B |
March 08, 2024 | 200.38B |
March 07, 2024 | 199.90B |
March 06, 2024 | 201.90B |
March 05, 2024 | 201.93B |
March 04, 2024 | 203.40B |
March 01, 2024 | 203.90B |
February 29, 2024 | 200.42B |
February 28, 2024 | 202.37B |
February 27, 2024 | 202.92B |
February 26, 2024 | 207.14B |
February 23, 2024 | 208.65B |
February 22, 2024 | 206.50B |
February 21, 2024 | 205.58B |
February 20, 2024 | 205.61B |
February 16, 2024 | 205.71B |
February 15, 2024 | 208.59B |
February 14, 2024 | 209.12B |
February 13, 2024 | 209.34B |
February 12, 2024 | 211.46B |
Date | Value |
---|---|
February 09, 2024 | 209.69B |
February 08, 2024 | 211.53B |
February 07, 2024 | 212.08B |
February 06, 2024 | 222.89B |
February 05, 2024 | 226.05B |
February 02, 2024 | 226.70B |
February 01, 2024 | 227.44B |
January 31, 2024 | 221.92B |
January 30, 2024 | 222.12B |
January 29, 2024 | 221.49B |
January 26, 2024 | 220.59B |
January 25, 2024 | 219.78B |
January 24, 2024 | 217.23B |
January 23, 2024 | 219.59B |
January 22, 2024 | 219.73B |
January 19, 2024 | 218.47B |
January 18, 2024 | 216.69B |
January 17, 2024 | 216.47B |
January 16, 2024 | 216.15B |
January 12, 2024 | 217.77B |
January 11, 2024 | 215.95B |
January 10, 2024 | 216.74B |
January 09, 2024 | 218.18B |
January 08, 2024 | 220.11B |
January 05, 2024 | 215.90B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
108.40B
Minimum
May 31 2019
227.44B
Maximum
Feb 01 2024
156.06B
Average
157.35B
Median
Enterprise Value Benchmarks
Gilead Sciences Inc | 108.90B |
Johnson & Johnson | 384.00B |
Eli Lilly and Co | 747.04B |
Merck & Co Inc | 335.58B |
Vertex Pharmaceuticals Inc | 94.97B |
Enterprise Value Related Metrics
Net Income (Quarterly) | 767.00M |
Revenue (Quarterly) | 8.196B |
Total Expenses (Quarterly) | 6.925B |
EPS Diluted (Quarterly) | 1.42 |
Gross Profit Margin (Quarterly) | 62.03% |
Profit Margin (Quarterly) | 9.36% |
Earnings Yield | 4.61% |
Operating Earnings Yield | 5.42% |
Normalized Earnings Yield | 4.611 |